BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morales AL, Junga Z, Singla MB, Sjogren M, Torres D. Hepatitis C eradication with sofosbuvir leads to significant metabolic changes. World J Hepatol 2016; 8(35): 1557-1563 [PMID: 28050236 DOI: 10.4254/wjh.v8.i35.1557] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Casas-deza D, Martínez-sapiña A, Espina S, Garcia-rodriguez B, Fernandez-bonilla EM, Sanz-paris A, Gonzalez-irazabal Y, Bernal-monterde V, Arbones-mainar JM. Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. JCM 2022;11:4049. [DOI: 10.3390/jcm11144049] [Reference Citation Analysis]
2 Abdel Fattah NK, Shaheen SM, Ahmed OA, Elsaeed K, Sabri NA. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Res 2022;11:649. [DOI: 10.12688/f1000research.109397.1] [Reference Citation Analysis]
3 Allam AS, Elmeged MLA, Ghaly SM, Ahmed OA, Naguib GG, Abohalima AS. Impact of direct-acting antiviral therapy on metabolic profiles and adiponectin serum level in different categories of patients with chronic hepatitis C infection. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00194-z] [Reference Citation Analysis]
4 Hagag RY, Selim AF, Darrag OM, Zied H, Aboelnasr MS. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy? Diabetes Metab Syndr Obes 2022;15:1261-8. [PMID: 35502409 DOI: 10.2147/DMSO.S354023] [Reference Citation Analysis]
5 Spaziante M, Taliani G, Marchetti G, Tavelli A, Lichtner M, Cingolani A, Cicalini S, Biliotti E, Girardi E, Antinori A, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021;13:1402. [PMID: 34372608 DOI: 10.3390/v13071402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
7 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Hino N, Sasaki R, Takahashi Y, Koike M, Fukushima M, Haraguchi M, Honda T, Miuma S, Ozawa E, Miyaaki H, Ichikawa T, Nakao K. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Intern Med 2021;60:191-9. [PMID: 33456023 DOI: 10.2169/internalmedicine.5563-20] [Reference Citation Analysis]
9 Özdoğan O, Yaraş S, Ateş F, Üçbilek E, Sezgin O, Altıntaş E. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent? Turk J Gastroenterol 2020;31:384-92. [PMID: 32519958 DOI: 10.5152/tjg.2020.19273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterología y Hepatología (English Edition) 2020;43:248-255. [DOI: 10.1016/j.gastre.2019.03.027] [Reference Citation Analysis]
11 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248-55. [PMID: 32192765 DOI: 10.1016/j.gastrohep.2019.03.017] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ribaldone DG, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. J Clin Med. 2020;9. [PMID: 32092892 DOI: 10.3390/jcm9020563] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
13 Mada PK, Malus ME, Parvathaneni A, Chen B, Castano G, Adley S, Moore M, Hieda M, Alam MJ, Feldman M, King JW. Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus. Int J Hepatol 2020;2020:6438753. [PMID: 32395351 DOI: 10.1155/2020/6438753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kalmykova ZA, Kononenko IV, Mayorov AY. [Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features]. Ter Arkh 2019;91:115-21. [PMID: 32598598 DOI: 10.26442/00403660.2019.12.000166] [Reference Citation Analysis]
15 Morihara D, Ko YL, Shibata K, Yamauchi R, Fukuda H, Tsuchiya N, Fukunaga A, Kunimoto H, Iwashita H, Takata K, Tanaka T, Sakurai K, Inomata S, Yokoyama K, Nishizawa S, Takeyama Y, Irie M, Shakado S, Sohda T, Sakisaka S. IL28B gene polymorphism is correlated with changes in low-density lipoprotein cholesterol levels after clearance of hepatitis C virus using direct-acting antiviral treatment. J Gastroenterol Hepatol 2019;34:2019-27. [PMID: 31144350 DOI: 10.1111/jgh.14741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Schmidt MA, Daida YG, Lu M; CHeCS Investigators. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int 2019;39:1027-32. [PMID: 30570808 DOI: 10.1111/liv.14031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
17 Li J. Letter: HCV complication and type 2 diabetes management-the directional link is not yet defined. Authors' reply. Aliment Pharmacol Ther 2019;49:1251-2. [PMID: 30977180 DOI: 10.1111/apt.15247] [Reference Citation Analysis]
18 Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. Cells 2019;8:E252. [PMID: 30884773 DOI: 10.3390/cells8030252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
19 Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Aboubakr AA, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S; Jury, Reviewers and Advisory Board: Sherif Abdelfattah, Samir Helmy ASSAAD-KHALIL, Ahmed Ali Elgarem, Rawia Khater, Amr Helmi, Hisham Elborlsy, Abdelhamid Attia (President of the Arab Federation Of Evidence-Based Medicine). Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). Arab J Gastroenterol 2019;20:61-3. [PMID: 30852101 DOI: 10.1016/j.ajg.2019.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Bhatti Z, Norsworthy J, Sivalingam D. Diabetes in a Hepatitis C and HIV-Coinfected Patient Treated With the Ledipasvir and Sofosbuvir Regimen. Am J Ther 2018;25:e391. [PMID: 29723164 DOI: 10.1097/MJT.0000000000000572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Narita S, Toda S, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hori T, Hirata R, Taura N, Nakao K. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. Intern Med 2019;58:1209-15. [PMID: 30626818 DOI: 10.2169/internalmedicine.1514-18] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
22 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
23 Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S. Managing diabetes and liver disease association. Arab J Gastroenterol 2018;19:166-79. [PMID: 30420265 DOI: 10.1016/j.ajg.2018.08.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
24 Cheng PN, Chiu YC, Chien SC, Chiu HC. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. J Formos Med Assoc 2019;118:907-13. [PMID: 30316677 DOI: 10.1016/j.jfma.2018.09.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
25 Andrade VG, Yamashiro FDS, Oliveira CV, Kurozawa LL, Moreira A, Silva GF. INCREASE OF LIPIDS DURING HCV TREATMENT: VIRUS ACTION OR MEDICATION? Arq Gastroenterol 2018;55:184-7. [PMID: 30043871 DOI: 10.1590/S0004-2803.201800000-33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
27 Adinolfi LE, Rinaldi L, Marrone A, Giordano M. The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. Expert Rev Anti Infect Ther. 2018;16:595-597. [PMID: 30047799 DOI: 10.1080/14787210.2018.1505500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
28 Olveira A, Domínguez L, Troya J, Arias A, Pulido F, Ryan P, Benítez LM, González-García J, Montes ML; PALT-M-Study Group Investigators. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. J Viral Hepat 2018;25:818-24. [PMID: 29476581 DOI: 10.1111/jvh.12883] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
29 Carvalho JR, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. Scand J Gastroenterol 2018;53:857-63. [PMID: 29779403 DOI: 10.1080/00365521.2018.1473486] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ikeda A, Ikeda K, Takai A, Takahashi K, Ueda Y, Marusawa H, Seno H, Inagaki N, Kokuryu H. Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion 2017;96:228-30. [PMID: 29084399 DOI: 10.1159/000484237] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
31 Kawaguchi T, Koga H, Torimura T. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Curr Hepatology Rep 2017;16:317-25. [DOI: 10.1007/s11901-017-0370-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Bilić-ćurčić I, Roguljić H, Ivandić M, Včev A, Smolić R, Smolić M. Hepatitis C–Associated Diabetes Mellitus. Update on Hepatitis C 2017. [DOI: 10.5772/intechopen.70721] [Reference Citation Analysis]
33 Kanda T, Moriyama M. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World J Gastroenterol 2017; 23(31): 5645-5649 [PMID: 28883690 DOI: 10.3748/wjg.v23.i31.5645] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
34 Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S, Nagy A, Hussein MS, Yosry A, Esmat G. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. J Med Virol. 2017;89:2181-2187. [PMID: 28688190 DOI: 10.1002/jmv.24897] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]